Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can alcohol consumption in early pregnancy harm fetal brain development?What is prilosec's mechanism for treating acid reflux?Can tailored sapropterin dosing improve treatment outcomes?Can sapropterin biomarkers predict treatment success?How does renal function impact tigecycline's liver safety?
See the DrugPatentWatch profile for lipitor
Can Lipitor interact with other drugs? Lipitor (atorvastatin) interacts with many common medications because it is broken down by the CYP3A4 enzyme in the liver. When other drugs inhibit this enzyme, atorvastatin levels rise, increasing the risk of muscle pain, weakness, or rare but serious muscle breakdown. What drugs raise Lipitor levels the most? Strong CYP3A4 inhibitors like itraconazole, ketoconazole, clarithromycin, and ritonavir cause the largest jumps in atorvastatin exposure. These combinations usually require dose reduction or temporary avoidance of Lipitor. Moderate inhibitors such as diltiazem, verapamil, and amlodipine require careful monitoring or dose limits. What happens if you take Lipitor with fibrates or niacin? Fibrates and niacin increase the risk of muscle-related side effects even without affecting CYP3A4. Patients who need both atorvastatin and gemfibrozil or fenofibrate receive lower Lipitor doses and receive frequent CK monitoring to detect early muscle damage. How does Lipitor interact with warfarin? Atorvastatin does not change warfarin’s effect on blood clotting in most patients. However, reports of raised INR and bleeding risk exist, so doctors check INR more closely when starting or changing Lipitor doses. When does the manufacturer recommend avoiding certain combinations? The official prescribing information lists absolute contraindications for Lipitor with strong CYP3A4 inhibitors like clarithromycin in some settings and with tipranavir/ritonavir or tipranavir/cyclosporine combinations. The company also warns against using hoary cress plant extracts or cyclosporine in certain high-risk patients. Why are companies challenging this patent? Companies are challenging the Lipitor patents because the basic compound protection ended in 2011, but additional patents on specific salt forms and crystal forms extended exclusivity until 2016.
Other Questions About Lipitor :